Neurocrine Biosciences Inc $ 101.65 -0.22 (-0.22%)
Volume:
1,176,611
Avg Vol (1m):
761,245
Market Cap $:
9.48 Bil
Enterprise Value $:
9.03 Bil
P/E (TTM):
48.19
P/B:
11.40
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.88 | ||
| Equity-to-Asset | 0.55 | ||
| Debt-to-Equity | 0.61 | ||
| Debt-to-EBITDA | 1.94 | ||
| Interest Coverage | 10.91 | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 9.06 | ||
| Beneish M-Score | -2.1 | ||
| WACC vs ROIC | |||
Profitability Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 35.45 | ||
| Net Margin % | 20.36 | ||
| ROE % | 31.73 | ||
| ROA % | 15.92 | ||
| ROC (Joel Greenblatt) % | 178.47 | ||
| 3-Year Revenue Growth Rate | 262.4 |
NBIX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 48.19 | ||
| Forward PE Ratio | 23.26 | ||
| PE Ratio without NRI | 48.19 | ||
| Price-to-Owner-Earnings | 52.04 | ||
| PB Ratio | 11.4 | ||
| PS Ratio | 9.84 | ||
| Price-to-Free-Cash-Flow | 28.63 | ||
| Price-to-Operating-Cash-Flow | 27.65 | ||
| EV-to-EBIT | 35.89 | ||
| EV-to-EBITDA | 34.74 | ||
| EV-to-Revenue | 8.98 | ||
| Current Ratio | 2 | ||
| Quick Ratio | 1.96 | ||
| Days Inventory | 661.65 | ||
| Days Sales Outstanding | 53.86 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 11.4 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 12.47 | ||
| Price-to-Graham-Number | 4.94 | ||
| Earnings Yield (Greenblatt) % | 2.8 |